Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Fortress Biotech (FBIO) over the last 16 years, with Dec 2024 value amounting to -$80.2 million.

  • Fortress Biotech's Free Cash Flow rose 67.26% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.1 million, marking a year-over-year increase of 35.31%. This contributed to the annual value of -$80.2 million for FY2024, which is 37.49% up from last year.
  • Per Fortress Biotech's latest filing, its Free Cash Flow stood at -$80.2 million for FY2024, which was up 37.49% from -$128.3 million recorded in FY2023.
  • Fortress Biotech's 5-year Free Cash Flow high stood at -$80.2 million for FY2024, and its period low was -$182.1 million during FY2022.
  • Over the past 3 years, Fortress Biotech's median Free Cash Flow value was -$128.3 million (recorded in 2023), while the average stood at -$130.2 million.
  • Per our database at Business Quant, Fortress Biotech's Free Cash Flow plummeted by 50.38% in 2022 and then surged by 37.49% in 2024.
  • Over the past 5 years, Fortress Biotech's Free Cash Flow (Yearly) stood at -$85.6 million in 2020, then tumbled by 41.47% to -$121.1 million in 2021, then tumbled by 50.38% to -$182.1 million in 2022, then increased by 29.56% to -$128.3 million in 2023, then soared by 37.49% to -$80.2 million in 2024.